Silvia G Priori

List of Publications by Year
in descending order

479 papers	96,143 citations	385 134 h-index	245 303 g-index
509 all docs	509 docs citations	509 times ranked	47236 citing authors

#	Article	IF	Citations
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
2	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal, 2015, 36, 2793-2867.	2.2	3,187
3	Universal Definition of Myocardial Infarction. Circulation, 2007, 116, 2634-2653.	1.6	2,755
4	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 2008, 29, 2388-2442.	2.2	2,656
5	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 rgBT /Over	2.2	2,331
6	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1664-1672.	1.6	2,308
7	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, e257-354.	1.6	2,120
8	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal, 2006, 28, 230-268.	2.2	1,802
9	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197.	2.2	1,694
10	Genotype-Phenotype Correlation in the Long-QT Syndrome. Circulation, 2001, 103, 89-95.	1.6	1,641
11	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, 1932-1963.	0.7	1,587
12	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1772-1778.	1.6	1,562
13	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 1687-1713.	2.8	1,444
14	CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism. Cell, 2004, 119, 19-31.	28.9	1,403
15	Risk Stratification in the Long-QT Syndrome. New England Journal of Medicine, 2003, 348, 1866-1874.	27.0	1,314
16	Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2001, 103, 196-200.	1.6	1,291
17	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346.	2.8	1,280
18	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal, 2006, 27, 1341-1381.	2.2	1,192

#	Article	IF	Citations
19	Spectrum of Mutations in Long-QT Syndrome Genes. Circulation, 2000, 102, 1178-1185.	1.6	1,157
20	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	2.2	1,144
21	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. European Heart Journal, 2005, 26, 384-416.	2.2	1,114
22	Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2002, 106, 69-74.	1.6	1,103
23	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillationâ€"Executive Summary. Journal of the American College of Cardiology, 2006, 48, 854-906.	2.8	1,044
24	Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. European Heart Journal, 2005, 26, 516-524.	2.2	1,037
25	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, e385-484.	1.6	1,031
26	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm, 2011, 8, 1308-1339.	0.7	995
27	Natural History of Brugada Syndrome. Circulation, 2002, 105, 1342-1347.	1.6	984
28	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.8	975
29	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278.	2.2	903
30	Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. European Heart Journal, 2005, 26, 1422-1445.	2.2	860
31	Low Penetrance in the Long-QT Syndrome. Circulation, 1999, 99, 529-533.	1.6	783
32	Effectiveness and Limitations of Î²-Blocker Therapy in Congenital Long-QT Syndrome. Circulation, 2000, 101, 616-623.	1.6	783
33	Proposed Diagnostic Criteria for the Brugada Syndrome. Circulation, 2002, 106, 2514-2519.	1.6	779
34	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2011, 123, e269-367.	1.6	747
35	Influence of the Genotype on the Clinical Course of the Long-QT Syndrome. New England Journal of Medicine, 1998, 339, 960-965.	27.0	728
36	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. European Heart Journal, 2020, 41, 2083-2088.	2.2	716

#	Article	IF	Citations
37	Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 2001, 22, 1374-1450.	2.2	699
38	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	1.7	699
39	Long QT Syndrome Patients With Mutations of the SCN5A and HERG Genes Have Differential Responses to Na ⁺ Channel Blockade and to Increases in Heart Rate. Circulation, 1995, 92, 3381-3386.	1.6	689
40	FKBP12.6 Deficiency and Defective Calcium Release Channel (Ryanodine Receptor) Function Linked to Exercise-Induced Sudden Cardiac Death. Cell, 2003, 113, 829-840.	28.9	683
41	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	661
42	Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmiasâˆ—âˆ—This document does not cover atrial fibrillation; atrial fibrillation is covered in the ACC/AHA/ESC guidelines on the management of patients with atrial fibrillation found on the ACC, AHA, and ESC Web sites.â€"executive summary. Journal of the American College of Cardiology, 2003, 42, 1493-1531.	2.8	660
43	ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmiasâ€"Executive Summary. Circulation, 2003, 108, 1871-1909.	1.6	651
44	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	1.7	635
45	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationâ€"executive summary. European Heart Journal, 2006, 27, 1979-2030.	2.2	612
46	Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary The Task Force on Infective Endocarditis of the European Society of Cardiology. European Heart Journal, 2004, 25, 267-276.	2.2	606
47	Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome. Circulation, 2004, 109, 1826-1833.	1.6	600
48	A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene. Circulation Research, 2005, 96, 800-807.	4.5	575
49	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq1 1 0.784314 rgBT /Over	1.7	546
50	Rhythm Association and the Heart R. Europace, 2006, 8, 746-837. Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With Î²-Blockers. JAMA - Journal of the American Medical Association, 2004, 292, 1341.	7.4	538
51	Risk Stratification in Brugada Syndrome. Journal of the American College of Cardiology, 2012, 59, 37-45.	2.8	523
52	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace, 2013, 15, 1389-1406.	1.7	494
53	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.7	494
54	Clinical and Genetic Heterogeneity of Right Bundle Branch Block and ST-Segment Elevation Syndrome. Circulation, 2000, 102, 2509-2515.	1.6	490

#	Article	IF	Citations
55	A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10613-10618.	7.1	466
56	Expert consensus document on ?-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology. European Heart Journal, 2004, 25, 1341-1362.	2.2	465
57	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) Tj ETQq1 1 0.784314 rgBT /Over	2.2	454
58	Age- and Sex-Related Differences in Clinical Manifestations in Patients With Congenital Long-QT Syndrome. Circulation, 1998, 97, 2237-2244.	1.6	451
59	Management of Grown Up Congenital Heart Disease. European Heart Journal, 2003, 24, 1035-1084.	2.2	446
60	Genetic Testing in the Long QT Syndrome. JAMA - Journal of the American Medical Association, 2005, 294, 2975.	7.4	413
61	Spectrum of ST-Tâ€"Wave Patterns and Repolarization Parameters in Congenital Long-QT Syndrome. Circulation, 2000, 102, 2849-2855.	1.6	409
62	Inherited Dysfunction of Sarcoplasmic Reticulum Ca ²⁺ Handling and Arrhythmogenesis. Circulation Research, 2011, 108, 871-883.	4.5	396
63	Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-goâ€"Related Gene Potassium Channel. Circulation, 2002, 105, 794-799.	1.6	370
64	Long QT Syndrome in Adults. Journal of the American College of Cardiology, 2007, 49, 329-337.	2.8	369
65	Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary. European Heart Journal, 2004, 25, 2054-2072.	2.2	360
66	A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart. Cell, 2020, 183, 94-109.e23.	28.9	360
67	Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome.. Circulation, 1994, 89, 1681-1689.	1.6	356
68	Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17533-17538.	7.1	349
69	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 rgBT /Over	2.8	345
70	Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019, 5, 32.	30.5	347
71	Drugs and Brugada syndrome patients: Review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm, 2009, 6, 1335-1341.	0.7	342
72	A Molecular Link between the Sudden Infant Death Syndrome and the Long-QT Syndrome. New England Journal of Medicine, 2000, 343, 262-267.	27.0	340

#	Article	IF	Citations
73	Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). European Heart Journal, 2007, 28, 2803-2817.	2.2	335
74	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. European Heart Journal, 2004, 25, 166-181.	2.2	334
75	Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. European Heart Journal, 2006, 27, 994-1005.	2.2	321
76	Cardiac Histological Substrate in Patients With Clinical Phenotype of Brugada Syndrome. Circulation, 2005, 112, 3680-3687.	1.6	317
77	Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Human Molecular Genetics, 1995, 4, 1603-1607.	2.9	316
78	Drug-Induced Torsades de Pointes and Implications for Drug Development. Journal of Cardiovascular Electrophysiology, 2004, 15, 475-495.	1.7	314
79	Evidence for a Cardiac Ion Channel Mutation Underlying Drugâ€Induced QT Prolongation and Lifeâ€Threatening Arrhythmias. Journal of Cardiovascular Electrophysiology, 2000, 11, 691-696.	1.7	312
80	Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate With a Brugada Syndrome Phenotype. Circulation, 2014, 129, 1092-1103.	1.6	305
81	A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9137-9142.	7.1	301
82	Long QT Syndrome and Pregnancy. Journal of the American College of Cardiology, 2007, 49, 1092-1098.	2.8	299
83	2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536.	1.7	297
84	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II. Circulation, 1999, 99, 518-528.	1.6	295
85	Arrhythmogenesis in Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Research, 2006, 99, 292-298.	4.5	293
86	European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis, 2007, 194, 1-45.	0.8	292
87	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations. Heart Rhythm, 2008, 5, 907-925.	0.7	279
88	High Efficacy of Î²-Blockers in Long-QT Syndrome Type 1. Circulation, 2009, 119, 215-221.	1.6	274
89	Risk for Life-Threatening Cardiac Events in Patients With Genotype-Confirmed Long-QT Syndrome and Normal-Range Corrected QT Intervals. Journal of the American College of Cardiology, 2011, 57, 51-59.	2.8	268
90	Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?. Circulation, 2010, 122, 1272-1282.	1.6	261

#	Article	IF	Citations
91	Sodium channel mutations and arrhythmias. Nature Reviews Cardiology, 2009, 6, 337-348.	13.7	260
92	Risk of Aborted Cardiac Arrest or Sudden Cardiac Death During Adolescence in the Long-QT Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1249.	7.4	258
93	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology, 2003, 42, 103-109.	2.8	257
94	Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome. Circulation, 2008, 117, 2184-2191.	1.6	255
95	Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace, 2007, 9, 1006-1023.	1.7	254
96	Arrhythmogenic Mechanisms in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Research, 2007, 101, 1039-1048.	4.5	252
97	Bidirectional Ventricular Tachycardia and Fibrillation Elicited in a Knock-In Mouse Model Carrier of a Mutation in the Cardiac Ryanodine Receptor. Circulation Research, 2005, 96, e77-82.	4.5	247
98	Brugada syndrome and sudden cardiac death in children. Lancet, The, 2000, 355, 808-809.	13.7	244
99	The Elusive Link Between LQT3 and Brugada Syndrome. Circulation, 2000, 102, 945-947.	1.6	243
100	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2020, 141, 1872-1884.	1.6	229
101	Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. Europace, 2008, 10, 336-346.	1.7	221
102	Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. American Journal of Cardiology, 1999, 84, 876-879.	1.6	219
103	Unified EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations: Developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Fail. Europace, 2008, 10, 707-725.	1.7	215
104	The European cardiac resynchronization therapy survey. European Heart Journal, 2009, 30, 2450-2460.	2.2	215
105	Genetics of Sudden Cardiac Death. Circulation Research, 2015, 116, 1919-1936.	4.5	211
106	Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. Journal of the American College of Cardiology, 2003, 41, 633-642.	2.8	201
107	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome. Circulation, 2016, 133, 622-630.	1.6	201
108	Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients. Circulation, 2007, 116, 1137-1144.	1.6	194

#	Article	IF	Citations
109	Novel Insight Into the Natural History of Short QT Syndrome. Journal of the American College of Cardiology, 2014, 63, 1300-1308.	2.8	191
110	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. Journal of the American College of Cardiology, 2016, 67, 1053-1058.	2.8	191
111	Clinical Phenotype and Functional Characterization of CASQ2 Mutations Associated With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2006, 114, 1012-1019.	1.6	189
112	Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. Journal of Cellular Physiology, 2002, 190, 1-6.	4.1	182
113	Inherited Brugada and Long QT-3 Syndrome Mutations of a Single Residue of the Cardiac Sodium Channel Confer Distinct Channel and Clinical Phenotypes. Journal of Biological Chemistry, 2001, 276, 30623-30630.	3.4	181
114	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. European Journal of Preventive Cardiology, 2017, 24, 41-69.	1.8	181
115	Protective effect of vagal stimulation on reperfusion arrhythmias in cats.. Circulation Research, 1987, 61, 429-435.	4.5	179
116	Abnormal Interactions of Calsequestrin With the Ryanodine Receptor Calcium Release Channel Complex Linked to Exercise-Induced Sudden Cardiac Death. Circulation Research, 2006, 98, 1151-1158.	4.5	179
117	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. Journal of Clinical Investigation, 2002, 110, 1201-1209.	8.2	172
118	Cellular Dysfunction of LQT5-MinK Mutants: Abnormalities of IKs, IKr and Trafficking in Long QT Syndrome. Human Molecular Genetics, 1999, 8, 1499-1507.	2.9	170
119	Acute heart failure congestion and perfusion statusÂâ€"Âimpact of the clinical classification on inâ€hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	7.1	170
120	Polymorphisms in the NOS1APGene Modulate QT Interval Duration and Risk of Arrhythmias in the Long QT Syndrome. Journal of the American College of Cardiology, 2010, 55, 2745-2752.	2.8	163
121	Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation.. Circulation, 1988, 78, 178-185.	1.6	159
122	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, e85-e108.	0.7	159
123	Abnormal Calcium Signaling and Sudden Cardiac Death Associated With Mutation of Calsequestrin. Circulation Research, 2004, 94, 471-477.	4.5	158
124	Inherited calcium channelopathies in the pathophysiology of arrhythmias. Nature Reviews Cardiology, 2012, 9, 561-575.	13.7	158
125	Molecular diagnosis in a child with sudden infant death syndrome. Lancet, The, 2001, 358, 1342-1343.	13.7	157
126	Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm, 2004, 1, 276-283.	0.7	156

#	Article	IF	Citations
127	Catecholaminergic Polymorphic Ventricular Tachycardia. Progress in Cardiovascular Diseases, 2008, 51, 23-30.	3.1	156
128	Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. European Heart Journal, 2009, 30, 2241-2248.	2.2	156
129	The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. European Heart Journal, 2006, 27, 1338-1340.	2.2	155
130	Evaluation of the Spatial Aspects of T-Wave Complexity in the Long-QT Syndrome. Circulation, 1997, 96, 3006-3012.	1.6	151
131	Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 2540-2550.	2.8	148
132	Differential Response to Na ⁺ Channel Blockade, Î²-Adrenergic Stimulation, and Rapid Pacing in a Cellular Model Mimicking the SCN5A and HERG Defects Present in the Long-QT Syndrome. Circulation Research, 1996, 78, 1009-1015.	4.5	148
133	Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 876-885.	2.8	146
134	A Recessive Variant of the Romano-Ward Long-QT Syndrome?. Circulation, 1998, 97, 2420-2425.	1.6	139
135	Increased Ca ²⁺ Sensitivity of the Ryanodine Receptor Mutant RyR2 ^{R4496C} Underlies Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Research, 2009, 104, 201-209.	4.5	137
136	Screening for Sudden Cardiac Death in the Young. Circulation, 2011, 123, 1911-1918.	1.6	137
137	Interplay Between Genetic Substrate, QTcÂDuration, and Arrhythmia Risk in Patients With Long QT Syndrome. Journal of the American College of Cardiology, 2018, 71, 1663-1671.	2.8	137
138	Update of the guidelines on sudden cardiac death of the European Society of Cardiology. European Heart Journal, 2003, 24, 13-15.	2.2	135
139	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.7	135
140	Long-QT Syndrome After Age 40. Circulation, 2008, 117, 2192-2201.	1.6	134
141	Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2007, 4, 675-678.	0.7	133
142	Sudden Cardiac Death and Genetic Ion Channelopathies. Circulation, 2012, 125, 2027-2034.	1.6	133
143	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Part III. Circulation, 1999, 99, 674-681.	1.6	131
144	Yield of Genetic Screening in Inherited Cardiac Channelopathies. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 6-15.	4.8	131

#	Article	IF	Citations
145	Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome. Journal of the American College of Cardiology, 2004, 44, 117-125.	2.8	130
146	KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4291-4296.	7.1	130
147	Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. JAMA Cardiology, 2017, 2, 759.	6.1	127
148	Unexpected Structural and Functional Consequences of the R33Q Homozygous Mutation in Cardiac Calsequestrin. Circulation Research, 2008, 103, 298-306.	4.5	124
149	Torsade de Pointes. Drugs, 1994, 47, 51-65.	10.9	122
150	Luminal Ca2+ Regulation of Single Cardiac Ryanodine Receptors: Insights Provided by Calsequestrin and its Mutants. Journal of General Physiology, 2008, 131, 325-334.	1.9	122
151	Cost-effectiveness of neonatal ECG screening for the long QT syndrome. European Heart Journal, 2006, 27, 1824-1832.	2.2	121
152	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 of Heart Failure, 2009, 11, 1143-1151.	7.1	118
153	Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. Journal of the American College of Cardiology, 2001, 37, 911-919.	2.8	115
154	Novel Arrhythmogenic Mechanism Revealed by a Long-QT Syndrome Mutation in the Cardiac Na+Channel. Circulation Research, 2001, 88, 740-745.	4.5	114
155	Molecular and Electrophysiological Bases of Catecholaminergic Polymorphic Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology, 2007, 18, 791-797.	1.7	113
156	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. Journal of Clinical Investigation, 2002, 110, 1201-1209.	8.2	113
157	Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. European Heart Journal, 2002, 23, 975-983.	2.2	112
158	ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmiasâ€"executive summary A Report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 212 T European Heart Journal, 2003, 24, 1857-1897.	2.2	111
159	How Really Rare Are Rare Diseases?:. Journal of Cardiovascular Electrophysiology, 2003, 14, 1120-1121.	1.7	110
160	Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome. Journal of the American College of Cardiology, 2011, 57, 941-950.	2.8	110
161	Short Communication: Flecainide Exerts an Antiarrhythmic Effect in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia by Increasing the Threshold for Triggered Activity. Circulation Research, 2011, 109, 291-295.	4.5	110
162	Genetics of sudden death: focus on inherited channelopathies. European Heart Journal, 2011, 32, 2109-2118.	2.2	106

#	Article	IF	Citations
163	CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death and Disease, 2013, 4, e843-e843.	6.3	105
164	A Newly Characterized SCN5A Mutation Underlying Brugada Syndrome Unmasked by Hyperthermia. Journal of Cardiovascular Electrophysiology, 2003, 14, 407-411.	1.7	103
165	Calmodulin kinase II inhibition prevents arrhythmias in RyR2R4496C+/â˜ mice with catecholaminergic polymorphic ventricular tachycardia. Journal of Molecular and Cellular Cardiology, 2011, 50, 214-222.	1.9	103
166	Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation. Heart Rhythm, 2009, 6, 1652-1659.	0.7	102
167	Carbon Monoxide Cardiotoxicity. Journal of Toxicology: Clinical Toxicology, 2001, 39, 35-44.	1.5	96
168	Purkinje Cells From RyR2 Mutant Mice Are Highly Arrhythmogenic But Responsive to Targeted Therapy. Circulation Research, 2010, 107, 512-519.	4.5	96
169	Genetically engineered SCN5A mutant pig hearts exhibit conduction defects and arrhythmias. Journal of Clinical Investigation, 2015, 125, 403-412.	8.2	93
170	Flecainide Test in Brugada Syndrome: A Reproducible but Risky Tool. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 338-341.	1.2	92
171	The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure, 2011, 13, 974-983.	7.1	91
172	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. Heart Rhythm, 2017, 14, e41-e44.	0.7	91
173	In the RyR2 ^{R4496C} Mouse Model of CPVT, Î²-Adrenergic Stimulation Induces Ca Waves by Increasing SR Ca Content and Not by Decreasing the Threshold for Ca Waves. Circulation Research, 2010, 107, 1483-1489.	4.5	90
174	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1748-H1756.	3.2	88
175	Single Delivery of an Adeno-Associated Viral Construct to Transfer the CASQ2 Gene to Knock-In Mice Affected by Catecholaminergic Polymorphic Ventricular Tachycardia Is Able to Cure the Disease From Birth to Advanced Age. Circulation, 2014, 129, 2673-2681.	1.6	88
176	New Mutations in the KVLQT1 Potassium Channel That Cause Long-QT Syndrome. Circulation, 1998, 97, 1264-1269.	1.6	87
177	Role of Genetic Analyses in Cardiology. Circulation, 2006, 113, 1130-1135.	1.6	87
178	The European CRT Survey: 1 year (9â€“15 months) followâ€up results. European Journal of Heart Failure, 2012, 14, 61-73.	7.1	87
179	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	1.7	86
180	Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. Journal of Clinical Investigation, 2005, 115, 2033-2038.	8.2	85

#	Article	IF	Citations
181	Catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2005, 2, 550-554.	0.7	84
182	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
183	Unravelling the interplay between hyperkalaemia, reninâ€"angiotensinâ€"aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESCâ€HFAâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	7.1	83
184	Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy. Journal of the American College of Cardiology, 2009, 54, 832-837.	2.8	82
185	Inherited Arrhythmogenic Diseases. Circulation Research, 2004, 94, 140-145.	4.5	81
186	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. European Heart Journal, 2014, 35, 3250-3257.	2.2	81
187	Sexâ€•and ageâ€•related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	7.1	81
188	Homozygous Deletion in KVLQT1 Associated With Jervell and Lange-Nielsen Syndrome. Circulation, 1999, 99, 1344-1347.	1.6	80
189	Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovascular Research, 2010, 87, 50-59.	3.8	80
190	Electrocardiographic Prediction of Abnormal Genotype in Congenital Long QT Syndrome: Experience in 101 Related Family Members. Journal of Cardiovascular Electrophysiology, 2001, 12, 455-461.	1.7	79
191	Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the lqt1 and lqt2 forms of congenital long qt syndrome. Journal of the American College of Cardiology, 2002, 39, 1984-1991.	2.8	79
192	Genetics of Cardiac Arrhythmias and Sudden Cardiac Death. Annals of the New York Academy of Sciences, 2004, 1015, 96-110.	3.8	79
193	ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. European Heart Journal, 2004, 25, 437-445.	2.2	78
194	Paradoxical Effect of Increased Diastolic Ca ²⁺ Release and Decreased Sinoatrial Node Activity in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2012, 126, 392-401.	1.6	77
195	Female Predominance and Transmission Distortion in the Long-QT Syndrome. New England Journal of Medicine, 2006, 355, 2744-2751.	27.0	76
196	Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2010, 7, 1122-1128.	0.7	75
197	Trafficking Defects and Gating Abnormalities of a Novel SCN5A Mutation Question Gene-Specific Therapy in Long QT Syndrome Type 3. Circulation Research, 2010, 106, 1374-1383.	4.5	73
198	Early afterdepolarizations induced in vivo by reperfusion of ischemic myocardium. A possible mechanism for reperfusion arrhythmias.. Circulation, 1990, 81, 1911-1920.	1.6	72

#	Article	IF	Citations
199	Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with the long QT syndrome. American Journal of Cardiology, 2000, 85, 457-461.	1.6	72
200	Clinical Implications for Affected Parents and Siblings of Probands With Long-QT Syndrome. Circulation, 2001, 104, 557-562.	1.6	71
201	Viral Gene Transfer Rescues Arrhythmogenic Phenotype and Ultrastructural Abnormalities in Adult Calsequestrin-Null Mice With Inherited Arrhythmias. Circulation Research, 2012, 110, 663-668.	4.5	71
202	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2018, 15, 1394-1401.	0.7	71
203	Location of Mutation in the KCNQ1 and Phenotypic Presentation of Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2003, 14, 1149-1153.	1.7	69
204	Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. International Journal of Cardiology, 2015, 190, 393-402.	1.7	69
205	Mechanisms of I _{Ks} suppression in LQT1 mutants. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H3003-H3011.	3.2	68
206	Cardiac ryanodine receptor calcium release deficiency syndrome. Science Translational Medicine, 2021, 13, .	12.4	68
207	A novel SCN5A mutation associated with long QT-3: altered inactivation kinetics and channel dysfunction. Physiological Genomics, 2002, 10, 191-197.	2.3	66
208	Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm, 2008, 5, 831-836.	0.7	65
209	Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autismâ€“epilepsy phenotype. Human Molecular Genetics, 2014, 23, 4875-4886.	2.9	65
210	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. Heart Rhythm, 2018, 15, 1457-1465.	0.7	65
211	Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety, 2007, 16, 882-890.	1.9	64
212	Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (RYR2). Circulation Research, 2017, 121, 525-536.	4.5	64
213	Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With ShortÂQTÂSyndrome. Journal of the American College of Cardiology, 2017, 70, 3010-3015.	2.8	64
214	Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3Î². Circulation, 2019, 140, 1188-1204.	1.6	62
215	The Phenotypic Spectrum of a MutationÂHotspot Responsible for theÂShort QT Syndrome. JACC: Clinical Electrophysiology, 2017, 3, 727-743.	3.2	58
216	Age of First Arrhythmic Event in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	57

#	Article	IF	Citations
217	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm, 2018, 15, 716-724.	0.7	57
218	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
219	Therapeutic Strategies for Long-QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 290-297.	4.8	56
220	Ryanodine receptor and calsequestrin in arrhythmogenesis: What we have learnt from genetic diseases and transgenic mice. Journal of Molecular and Cellular Cardiology, 2009, 46, 149-159.	1.9	56
221	Induced pluripotent stem cellâ€"derived cardiomyocytes in studies of inherited arrhythmias. Journal of Clinical Investigation, 2013, 123, 84-91.	8.2	56
222	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
223	The long QT syndrome. Europace, 2001, 3, 16-27.	1.7	54
224	Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. Cardiovascular Research, 2007, 77, 293-301.	3.8	53
225	Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca ²⁺ release in a genetic model of arrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10312-10317.	7.1	53
226	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2019, 73, 1756-1765.	2.8	53
227	Programmed Electrical Stimulation in Brugada Syndrome: How Reproducible Are the Results?. Journal of Cardiovascular Electrophysiology, 2002, 13, 880-887.	1.7	52
228	Clinical spectrum of patients with a Brugada ECG. Current Opinion in Cardiology, 2009, 24, 74-81.	1.8	51
229	Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. Cell Death and Disease, 2016, 7, e2393-e2393.	6.3	51
230	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 1-28.	1.2	49
231	Left Ventricular Myocardial Work in Patients with Severe Aortic Stenosis. Journal of the American Society of Echocardiography, 2021, 34, 257-266.	2.8	49
232	Postmortem Molecular Analysis in Victims of Sudden Unexplained Death. American Journal of Forensic Medicine and Pathology, 2004, 25, 182-184.	0.8	48
233	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Revista Espanola De Cardiologia (English Ed), 2016, 69, 176.	0.6	48
234	Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation. Circulation Research, 2019, 124, 539-552.	4.5	48

#	Article	IF	Citations
235	Psychological Stress Preceding Idiopathic Ventricular Fibrillation. Psychosomatic Medicine, 2005, 67, 359-365.	2.0	47
236	Subclinical Abnormalities in Sarcoplasmic Reticulum Ca2+ Release Promote Eccentric Myocardial Remodeling and Pump Failure Death in Response to Pressure Overload. Journal of the American College of Cardiology, 2014, 63, 1569-1579.	2.8	47
237	Unexplained cardiac arrest, The need for a prospective registry. European Heart Journal, 1992, 13, 1445-1446.	2.2	46
238	C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3Ïµ. Human Molecular Genetics, 2006, 15, 2888-2902.	2.9	45
239	Abnormal Propagation of Calcium Waves and Ultrastructural Remodeling in Recessive Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation Research, 2013, 113, 142-152.	4.5	44
240	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms ofCASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2020, 142, 932-947.	1.6	44
241	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. Journal of the American College of Cardiology, 2020, 75, 1772-1784.	2.8	44
242	Sympathetic activation, ventricular repolarization and Ikrblockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents. Journal of the American College of Cardiology, 1995, 25, 1609-1614.	2.8	43
243	Exploring the Hidden Danger of Noncardiac Drugs. Journal of Cardiovascular Electrophysiology, 1998, 9, 1114-1116.	1.7	42
244	Concealed arrhythmogenic syndromes: the hidden substrate of idiopathic ventricular fibrillation?. Cardiovascular Research, 2001, 50, 218-223.	3.8	42
245	Catecholaminergic polymorphic ventricular tachycardia-related mutations R33Q and L167H alter calcium sensitivity of human cardiac calsequestrin. Biochemical Journal, 2008, 413, 291-303.	3.7	42
246	Y1767C, a novel SCN5A mutation, induces a persistent Na⁺ current and potentiates ranolazine inhibition of Na_v1.5 channels. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H288-H299.	3.2	42
247	Gene therapy to treat cardiac arrhythmias. Nature Reviews Cardiology, 2015, 12, 531-546.	13.7	42
248	Catecholaminergic Polymorphic Ventricular Tachycardia. Herz, 2007, 32, 212-217.	1.1	41
249	Molecular Biology of the Long QT Syndrome: Impact on Management. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2052-2057.	1.2	40
250	An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439.	1.6	39
251	Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release. Cardiovascular Research, 2015, 106, 143-152.	3.8	38
252	Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung and Circulation, 2016, 25, 777-783.	0.4	38

#	Article	IF	Citations
253	ESC Core Curriculum for the Cardiologist. European Heart Journal, 2020, 41, 3605-3692.	2.2	38
254	Evidence-based vs. â€˜impressionistâ€™ medicine: how best to implement guidelinesThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 1155-1158.	2.2	36
255	Genetics of ion-channel disorders. Current Opinion in Cardiology, 2012, 27, 242-252.	1.8	36
256	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€ÊORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	7.1	36
257	The Fifteen Years of Discoveries That Shaped Molecular Electrophysiology. Circulation Research, 2010, 107, 451-456.	4.5	35
258	GenÃ©tica y arritmias: aplicaciones diagnÃ³sticas y pronÃ³sticas. Revista Espanola De Cardiologia, 2012, 65, 278-286.	1.2	35
259	Suppression of Arrhythmia by EnhancingÂMitochondrial Ca2+ Uptake inÂCatecholaminergic Ventricular Tachycardia Models. JACC Basic To Translational Science, 2017, 2, 737-747.	4.1	35
260	Sacubitril/valsartan eligibility and outcomes in the ESCâ€ÊORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	7.1	35
261	Gender-specific prescription for cardiovascular diseases?. European Heart Journal, 2005, 26, 1571-1572.	2.2	34
262	Overexpression of CaMKIIÎ´c in RyR2R4496C+/â^' Knock-In Mice Leads to Altered Intracellular Ca2+ Handling and Increased Mortality. Journal of the American College of Cardiology, 2011, 57, 469-479.	2.8	34
263	Late gadolinium enhancement by cardiovascular magnetic resonance is complementary to left ventricle ejection fraction in predicting prognosis of patients with stable coronary artery disease. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 28.	3.3	34
264	Variable Expression of Long QT Syndrome Among Gene Carriers from Families with Five Different HERG Mutations. Annals of Noninvasive Electrocardiology, 2001, 7, 40-46.	1.1	33
265	Brugada syndrome. Orphanet Journal of Rare Diseases, 2006, 1, 35.	2.7	33
266	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. Expert Review of Cardiovascular Therapy, 2014, 12, 499-519.	1.5	33
267	Enhancement of Cardiac Store Operated Calcium Entry (SOCE) within Novel Intercalated Disk Microdomains in Arrhythmic Disease. Scientific Reports, 2019, 9, 10179.	3.3	33
268	Inherited arrhythmia syndromes: applying the molecular biology and genetic to the clinical management. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 93-101.	1.3	32
269	Medical Practice Guidelines Separating science from economics. European Heart Journal, 2003, 24, 1962-1964.	2.2	32
270	Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening. Prenatal Diagnosis, 2010, 30, 229-234.	2.3	32

#	Article	IF	Citations
271	Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrinâ€Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. Journal of the American Heart Association, 2018, 7, .	3.7	32
272	International Triadin Knockout Syndrome Registry. Circulation Genomic and Precision Medicine, 2019, 12, e002419.	3.6	32
273	Cardiac Sodium Channel Diseases. Clinical Chemistry and Laboratory Medicine, 2003, 41, 439-44.	2.3	31
274	Neuronal Na+ Channels Are Integral Components of Pro-Arrhythmic Na+/Ca2+ Signaling Nanodomain That Promotes Cardiac Arrhythmias During Î²-Adrenergic Stimulation. JACC Basic To Translational Science, 2016, 1, 251-266.	4.1	31
275	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. Human Mutation, 2018, 39, 1835-1846.	2.5	31
276	Cell identity and nucleo-mitochondrial genetic context modulate OXPHOS performance and determine somatic heteroplasmy dynamics. Science Advances, 2020, 6, eaba5345.	10.3	31
277	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. Circulation, 2020, 142, 513-515.	1.6	31
278	Efficacy of diltiazem in two experimental feline models of sudden cardiac death. Journal of the American College of Cardiology, 1986, 8, 661-668.	2.8	29
279	Policy Statement. Resuscitation, 2004, 60, 245-252.	3.0	29
280	Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity. Journal of Cardiovascular Medicine, 2006, 7, 250-256.	1.5	29
281	Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure, 2008, 10, 1229-1235.	7.1	29
282	IK1 modulates the U-wave: insights in a 100-year-old enigma. Heart Rhythm, 2009, 6, 393-400.	0.7	29
283	The Long QT Syndrome. Annals of Noninvasive Electrocardiology, 1998, 3, 63-73.	1.1	28
284	Cathecolaminergic Polymorphic Ventricular Tachycardia. Pediatric Emergency Care, 2004, 20, 175-177.	0.9	28
285	The Brugada syndrome. Current Opinion in Cardiology, 2007, 22, 163-170.	1.8	28
286	Electrocardiographic features of sudden unexpected death in epilepsy. Epilepsia, 2016, 57, e135-9.	5.1	28
287	The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. Europace, 2011, 13, 1445-1453.	1.7	27
288	Risk Stratification in the Long QT Syndrome. Cardiac Electrophysiology Clinics, 2012, 4, 53-60.	1.7	27

#	Article	IF	Citations
289	Big Data as a Driver for Clinical Decision Support Systems: A Learning Health Systems Perspective. Frontiers in Digital Humanities, 2018, 5, .	1.2	27
290	Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. Circulation, 2005, 112, 279-92; discussion 279-92.	1.6	27
291	A Clinical Approach to Inherited Arrhythmias. Circulation: Cardiovascular Genetics, 2012, 5, 581-590.	5.1	26
292	An ICT infrastructure to integrate clinical and molecular data in oncology research. BMC Bioinformatics, 2012, 13, S5.	2.6	26
293	The new kids on the block of arrhythmogenic disorders: Short QT syndrome and early repolarization. Journal of Cardiovascular Electrophysiology, 2017, 28, 1226-1236.	1.7	26
294	Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia. Journal of the American College of Cardiology, 2021, 77, 2592-2612.	2.8	26
295	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). Europace, 2022, 24, 614-619.	1.7	26
296	Loss of function associated with novel mutations of the SCN5A gene in patients with Brugada syndrome. Canadian Journal of Cardiology, 2004, 20, 425-30.	1.7	26
297	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With Î²-Blockers. JAMA Cardiology, 2022, 7, 504.	6.1	26
298	Intracellular Calcium Handling Dysfunction and Arrhythmogenesis. Circulation Research, 2005, 97, 1077-1079.	4.5	25
299	Gene-specific therapy for inherited arrhythmogenic diseases. , 2006, 110, 1-13.		25
300	From decision to shared-decision: Introducing patientsâ€™ preferences into clinical decision analysis. Artificial Intelligence in Medicine, 2015, 65, 19-28.	6.5	25
301	Long QT Syndrome: Genotype-Phenotype Correlations. , 2004, , 651-659.		25
302	Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: Effect of nifedipine. American Heart Journal, 1988, 116, 37-43.	2.7	24
303	Influence of hypoxia on adrenergic modulation of triggered activity in isolated adult canine myocytes.. Circulation, 1991, 83, 248-259.	1.6	24
304	Inferior Vena Cava Loop of the Implantable Cardioverter Defibrillator Endocardial Lead: A Possible Solution to the Growth Problem in Pediatric Implantation. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 2108-2112.	1.2	24
305	Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes. Cardiovascular Drugs and Therapy, 2002, 16, 89-92.	2.6	24
306	Barriers to implementation of evidence-based electrical therapies and the need for outcome research: role of European registries. Europace, 2011, 13, ii18-ii20.	1.7	24

#	Article	IF	Citations
307	Cardiac Damage in Pediatric Carbon Monoxide Poisoning. Journal of Toxicology: Clinical Toxicology, 2001, 39, 45-51.	1.5	23
308	Catecholaminergic Polymorphic Ventricular Tachycardia, Recurrent Syncope, and Implantable Loop Recorder. Journal of Cardiovascular Electrophysiology, 2004, 15, 729-729.	1.7	23
309	In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H56-H65.	3.2	23
310	hERG Blockade by Iboga Alkaloids. Cardiovascular Toxicology, 2016, 16, 14-22.	2.7	23
311	Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death. Bioscience Reports, 2021, 41, .	2.4	23
312	Long QT and Brugada Syndromes: From Genetics to Clinical Management. Journal of Cardiovascular Electrophysiology, 2000, 11, 1174-1178.	1.7	22
313	Significance of QT dispersion in the long QT syndrome. Progress in Cardiovascular Diseases, 2000, 42, 345-350.	3.1	22
314	R4496C RyR2 mutation impairs atrial and ventricular contractility. Journal of General Physiology, 2016, 147, 39-52.	1.9	22
315	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2019, 16, 1468-1474.	0.7	22
316	European Heart Rhythm Association Guidance Document on cardiac rhythm management product performance. Europace, 2006, 8, 313-322.	1.7	20
317	Electrophysiologic mechanisms involved in the development of torsades de pointes. Cardiovascular Drugs and Therapy, 1991, 5, 203-212.	2.6	19
318	Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. European Neuropsychopharmacology, 2010, 20, 829-838.	0.7	19
319	Genetic modulators of the phenotype in the long QT syndrome: state of the art and clinical impact. Current Opinion in Genetics and Development, 2015, 33, 17-24.	3.3	19
320	Clinical diagnosis of long QT syndrome: back to the caliper. European Heart Journal, 2006, 28, 527-528.	2.2	17
321	To Replace or Not to Replace: A Systematic Approach to Respond to Device Advisories. Journal of Cardiovascular Electrophysiology, 2009, 20, 164-170.	1.7	17
322	R Engine Cell: integrating R into the i2b2 software infrastructure. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 314-317.	4.4	17
323	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. Journal of Cardiovascular Electrophysiology, 2016, 27, 937-943.	1.7	17
324	Heritability in genetic heart disease: the role of genetic background. Open Heart, 2019, 6, e000929.	2.3	17

#	Article	IF	Citations
325	Foretelling the Future in Brugada Syndrome: Do We Have the Crystal Ball?. Journal of Cardiovascular Electrophysiology, 2001, 12, 1008-1009.	1.7	16
326	Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Long QT Syndrome: Is Personalized Medicine Ready for Prime Time?. Circulation Research, 2011, 109, 822-824.	4.5	16
327	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 29-47.	1.2	16
328	Use of Whole Exome Sequencing for the Identification of I _{to} â€Based Arrhythmia Mechanism and Therapy. Journal of the American Heart Association, 2015, 4, .	3.7	16
329	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Europace, 2019, 21, 796-802.	1.7	16
330	Genetic testing to predict sudden cardiac death: current perspectives and future goals. Indian Heart Journal, 2014, 66, S58-S60.	0.5	15
331	Information extraction from Italian medical reports: An ontology-driven approach. International Journal of Medical Informatics, 2018, 111, 140-148.	3.3	15
332	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	2.2	15
333	TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias. European Heart Journal, 2022, 43, 4195-4207.	2.2	15
334	Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing. American Journal of Cardiology, 1987, 60, 1068-1072.	1.6	14
335	European cardiac resynchronization therapy survey: rationale and design. European Journal of Heart Failure, 2009, 11, 326-330.	7.1	14
336	Molecular Autopsy for Sudden Unexplained Death? Time to Discuss Pros and Cons. Journal of Cardiovascular Electrophysiology, 2012, 23, 1099-1102.	1.7	14
337	Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type 1. European Journal of Medical Genetics, 2015, 58, 332-335.	1.3	14
338	J-Wave Syndromes. Cardiac Electrophysiology Clinics, 2018, 10, 355-369.	1.7	14
339	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2019, 12, .	4.8	14
340	Genetics of Long QT, Brugada, and Other Channelopathies. , 2004, , 462-470.		13
341	Molecular Underpinning of â€œGood Luckâ€. Circulation, 2006, 114, 360-362.	1.6	12
342	Role of the JP45-Calsequestrin Complex on Calcium Entry in Slow Twitch Skeletal Muscles. Journal of Biological Chemistry, 2016, 291, 14555-14565.	3.4	12

#	Article	IF	Citations
343	Implantable Loop Recorder in Inherited Arrhythmia Diseases. JACC: Clinical Electrophysiology, 2018, 4, 1372-1374.	3.2	12
344	Supervised methods to extract clinical events from cardiology reports in Italian. Journal of Biomedical Informatics, 2019, 95, 103219.	4.3	12
345	Rationale and design of the Pan-African Sudden Cardiac Death survey: the Pan-African SCD study : cardiovascular topic. Cardiovascular Journal of Africa, 2014, 25, 176-184.	0.4	12
346	Lack of correlation between occlusion and reperfusion arrhythmias in the cat. American Heart Journal, 1985, 109, 932-936.	2.7	11
347	Left Cardiac Sympathetic Denervation in Long QT Syndrome Patients. Journal of Interventional Cardiology, 1995, 8, 776-781.	1.2	11
348	Genetics of ventricular tachycardia. Current Opinion in Cardiology, 2002, 17, 222-228.	1.8	11
349	Computer simulation of wild-type and mutant human cardiac Na+ current. Medical and Biological Engineering and Computing, 2006, 44, 35-44.	2.8	11
350	The genetics of cardiomyopathy: Genotyping and genetic counseling. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 433-446.	0.9	11
351	RyRCa2+ Leak Limits Cardiac Ca2+ Window Current Overcoming the Tonic Effect of Calmodulin in Mice. PLoS ONE, 2011, 6, e20863.	2.5	11
352	Flecainide and Antiarrhythmic Effects in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. Trends in Cardiovascular Medicine, 2012, 22, 35-39.	4.9	11
353	Timothy Syndrome. , 2014, , 953-957.		11
354	Is There a Role for Genetics in the Prevention of Sudden Cardiac Death?. Journal of Cardiovascular Electrophysiology, 2016, 27, 1124-1132.	1.7	11
355	Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. Current Opinion in Pediatrics, 2017, 29, 552-559.	2.0	11
356	Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the CACNA1 Gene Associated With Brugada Syndrome. Frontiers in Physiology, 2020, 11, 616819.	2.8	11
357	Genetics and Arrhythmias: Diagnostic and Prognostic Applications. Revista Espanola De Cardiologia (English Ed), 2012, 65, 278-286.	0.6	9
358	Epidemiology of sudden cardiac death in Cameroon: Rationale and design of the Douala-SUD survey. Archives of Cardiovascular Diseases, 2014, 107, 433-442.	1.6	9
359	Genetic causes of sudden cardiac death in the young. Current Opinion in Cardiology, 2017, 32, 253-261.	1.8	9
360	Genetic risk stratification in cardiac arrhythmias. Current Opinion in Cardiology, 2018, 33, 298-303.	1.8	9

#	Article	IF	Citations
361	Catecholaminergic Polymorphic Ventricular Tachycardia and Short-coupled Torsades de Pointes. , 2004, , 633-639.		9
362	From catheters to vectors: the dawn of molecular electrophysiology. Nature Medicine, 2000, 6, 1316-1318.	30.7	8
363	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversiÃ³n de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	1.2	8
364	The Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia*. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S52-7.	1.2	8
365	When is genetic testing useful in patients suspected to have inherited cardiac arrhythmias?. Current Opinion in Cardiology, 2010, 25, 37-45.	1.8	8
366	Cardiac Magnetic Resonance in Stable Coronary Artery Disease: Added Prognostic Value to Conventional Risk Profiling. BioMed Research International, 2018, 2018, 1-10.	1.9	8
367	Additional diagnostic value of cardiac magnetic resonance feature tracking in patients with biopsy-proven arrhythmogenic cardiomyopathy. International Journal of Cardiology, 2021, 339, 203-210.	1.7	8
368	Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-up. American Heart Journal, 1989, 117, 1258-1264.	2.7	7
369	Idiopathic Ventricular Fibrillation. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 198-201.	1.0	7
370	Role of calmodulin kinase in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2011, 8, 1601-1605.	0.7	7
371	Stabilizer Cell Gene Therapy. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008420.	4.8	7
372	Genotype-Phenotype Correlation of SCN5A Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands. Circulation Genomic and Precision Medicine, 2021, 14, e003222.	3.6	7
373	Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003391.	3.6	7
374	Multiple comparison of several antiarrhythmic agents by acute oral drug testing in patients with chronic ventricular arrhythmias. European Heart Journal, 1988, 9, 462-470.	2.2	6
375	Endocardial Implantation of a Cardioverter-Defibrillator in a 13-Month-Old Child Affected by Long-QT Syndrome and Syndactyly. Circulation, 2004, 110, e525-7.	1.6	6
376	Epidemiology of Cardiac Arrest. , 0, , 1-20.		6
377	The Importance of Î±-Adrenergic Stimulation of Cardiac Tissue and its Contribution to Arrhythmogenesis During Ischemia. Journal of Cardiovascular Electrophysiology, 1990, 1, 529-542.	1.7	5
378	Endocardial Implantation of a Cardioverter Defibrillator in Early Childhood. Journal of Cardiovascular Electrophysiology, 2005, 16, 1381-1383.	1.7	5

#	Article	IF	Citations
379	From Genes to Cell Therapy: Molecular Medicine Meets Clinical EP. Journal of Cardiovascular Electrophysiology, 2005, 16, 552-552.	1.7	5
380	Charcot-Marie-Tooth type 1a in a child with Long QT syndrome. European Journal of Paediatric Neurology, 2009, 13, 459-462.	1.6	5
381	Unexplained sudden cardiac deathâ€"back to clinical evaluation. Nature Reviews Cardiology, 2009, 6, 678-679.	13.7	5
382	Meandering Pathway Leading From Genotyping to Personalized Management of Long-QT Syndrome. Circulation, 2012, 125, 1961-1963.	1.6	5
383	Brugada Syndrome. Journal of the American College of Cardiology, 2016, 68, 624-625.	2.8	5
384	Tetrodotoxinâ€Sensitive Neuronalâ€Type Na ⁺ Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e015119.	3.7	5
385	Management of Congenital Long-QT Syndrome: Commentary From the Experts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009726.	4.8	5
386	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 244-247.	1.0	4
387	To the Editor. Journal of Cardiovascular Electrophysiology, 2003, 14, 1131-1133.	1.7	4
388	Routine electrocardiogram and medical history in syncope: a simple approach can identify most high-risk patients. Europace, 2009, 11, 1411-1412.	1.7	4
389	Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome. Journal of the American College of Cardiology, 2019, 73, 1868-1869.	2.8	4
390	Evolving determinants of carotid atherosclerosis vulnerability in asymptomatic patients from the MAGNETIC observational study. Scientific Reports, 2021, 11, 2327.	3.3	4
391	Recurrent Neural Network Architectures for Event Extraction from Italian Medical Reports. Lecture Notes in Computer Science, 2017, , 198-202.	1.3	4
392	Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients. Frontiers in Pharmacology, 2020, 11, 580481.	3.5	4
393	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): commentâ€"Authors' reply. Europace, 2022, 24, 698-699.	1.7	4
394	Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium. Cardiovascular Drugs and Therapy, 1991, 5, 67-76.	2.6	3
395	Romano-Ward and other congenital long QT syndromes. Cardiovascular Drugs and Therapy, 2002, 16, 19-23.	2.6	3
396	From trials to guidelines to clinical practice: the need for improvement. Europace, 2004, 6, 176-178.	1.7	3

#	Article	IF	Citations
397	Arrhythmogenic Mechanism of Catecholaminergic Polymorphic Ventricular Tachycardia. Journal of Arrhythmia, 2006, 22, 202-208.	1.2	3
398	Letters Regarding Article by Coronel et al, â€œRight Ventricular Fibrosis and Conduction Delay in a Patient With Clinical Signs of Brugada Syndrome: A Combined Electrophysiological, Genetic, Histopathologic, and Computational Studyâ€• Circulation, 2006, 113, e726; author reply 726-7.	1.6	3
399	The fight against sudden cardiac death: consensus guidelines as a reference. Country Review Ukraine, 2007, 9, 150-158.	0.8	3
400	ST-Segment Elevation in the Setting of a Febrile Illness. , 2011, 16, 303-307.		3
401	Genetic Determinants of Cardiac (Electric) Conduction. Circulation Research, 2011, 108, 402-403.	4.5	3
402	Congenital Long QT Syndrome Type 3. Cardiac Electrophysiology Clinics, 2014, 6, 705-713.	1.7	3
403	Inherited conditions of arrhythmia: translating disease mechanisms to patient management. Cardiovascular Research, 2020, 116, 1539-1541.	3.8	3
404	Sudden cardiac death in the young: Are we still missing the opportunity to prevent recurrences in the family?. Heart Rhythm, 2021, 18, 1645-1646.	0.7	3
405	Erratum Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 2002, 23, 257.	2.2	2
406	Drug-Induced Sudden Death. , 0, , 177-188.		2
407	Inherited Arrhythmogenic Diseases. , 0, , 132-146.		2
408	Reply. Journal of the American College of Cardiology, 2017, 69, 248-249.	2.8	2
409	Digital transformation of major scientific meetings induced by the COVID-19 pandemic: insights from the ESC 2020 annual congress. European Heart Journal Digital Health, 2021, 2, 704-712.	1.7	2
410	Desmoplakin cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy: two distinct forms of cardiomyopathy?. Minerva Cardiology and Angiology, 2022, 70, .	0.7	2
411	Preventing sudden death: the role of the internist. European Journal of Internal Medicine, 2003, 14, 75-76.	2.2	1
412	Risk Stratification for SCD. , 0, , 47-61.		1
413	Clinical Characteristics of Sudden Cardiac Death Victims and Precipitating Events. , 0, , 74-87.		1
414	Taking the importance of cardiovascular disease in women to heart. Lancet, The, 2006, 368, 637-638.	13.7	1

#	Article	IF	Citations
415	Ouabain is a Pharmacomimic of Mutant RyR2 Ca2+ Release Dysfunction but is not a Serum-Borne Trigger of CPVT. Biophysical Journal, 2011, 100, 412a-413a.	0.5	1
416	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [Europace 2011;13:1077-109, doi: 10.1093/europace/eur245]. Europace, 2012, 14, 277-277.	1.7	1
417	Diagnosis of Long QT Syndrome: Time to Stand Up!. Revista Espanola De Cardiologia (English Ed), 2017, 70, 898-900.	0.6	1
418	DiagnÃ³stico del sÃndrome de QT largo: valor del ortostatismo. Revista Espanola De Cardiologia, 2017, 70, 898-900.	1.2	1
419	Gene Therapy to Treat Cardiac Arrhythmias. , 2018, , 531-540.		1
420	Timothy Syndrome. , 2018, , 910-916.		1
421	Warning: not all carriers of pathogenic mutations in desmosomal genes should follow the same medical advices!. Cardiovascular Research, 2020, 116, 1085-1088.	3.8	1
422	L-Type Calcium Channel Disease. , 2013, , 209-217.		1
423	The Long QT Syndrome. Contemporary Cardiology, 2003, , 169-185.	0.1	1
424	Catecholaminergic Polymorphic Ventricular Tachycardia. , 2013, , 551-560.		1
425	Cardiac ryanodine receptors: is a severe loss-of-function not so severe after all?. Europace, 2022, 24, 494-496.	1.7	1
426	GPIIb/IIIa polymorphism in patients with myocardial infarction. Acta Cardiologica, 2002, 57, 32-3.	0.9	1
427	Abstract 23071: Hydroquinidine Abolishes Life-threatening Arrhythmic Events in Patients With Short QT Syndrome. Circulation, 2017, 136, .	1.6	1
428	Spotlight on sudden cardiac death. Cardiovascular Research, 2001, 50, 173-176.	3.8	0
429	Cost-Effectiveness of Implantable Cardioverter-Defibrillators. , 0, , 263-279.		0
430	Arrhythmogenic Mechanisms. , 0, , 33-46.		0
431	Sudden Cardiac Death and Valvular Heart Diseases. , 0, , 147-161.		0
432	Sudden Death in Athletes. , 0, , 189-202.		0

#	Article	IF	Citations
433	Pharmacology of Sudden Cardiac Death. , 0, , 203-219.		0
434	Implantable Devices. , 0, , 220-236.		0
435	Sudden Cardiac Death: Ablation. , 0, , 237-248.		0
436	External Automated Defibrillators. , 0, , 249-262.		0
437	Genetic Predisposition and Pathology of Sudden Cardiacdeath. , 0, , 21-32.		0
438	Autonomic Nervous System: Emerging Concepts and Clinical Applications. , 0, , 62-73.		0
439	The Cardiomyopathies. , 0, , 109-131.		0
440	Evidence-based vs. 'impressionist' medicine: how best to implement guidelines: reply. European Heart Journal, 2005, 26, 2474-2475.	2.2	0
441	AB23-1. Heart Rhythm, 2006, 3, S47.	0.7	0
442	Current Strategies to Diminish the Impact of Cardiovascular Diseases in Women. Revista Espanola De Cardiologia (English Ed), 2006, 59, 1190-1193.	0.6	0
443	Genetics, genomics and proteomics in sudden cardiac death. , 0, , 70-89.		0
444	Molecular strategies for the electrophysiologist. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 117-117.	3.3	0
445	Impact of RyR2 Mutation Responsible for Cathecolaminergic Polymorphic Ventricular Tachycardia (CPTV) on the Short Term Interval-Force Relationship of Atrial and Ventricular Myocardium. Biophysical Journal, 2009, 96, 111a.	0.5	0
446	Preface. Cardiac Electrophysiology Clinics, 2010, 2, xv-xvii.	1.7	0
447	Impact of R4496C RyR2 Mutation on Myocardial Contractility. Biophysical Journal, 2011, 100, 291a.	0.5	0
448	Increased Heart Failure Development After Pressure Overload-Induced Hypertrophy in Mice with a RyR2-R4496C+/- Knock-In Mutation. Biophysical Journal, 2011, 100, 291a.	0.5	0
449	Intracellular Calcium Handling and Inherited Arrhythmogenic Diseases. , 2011, , 387-408.		0
450	Increased Levels of miR-1 Exacerbate Cardiac Arrhythmia Linked to Gain-Of- Function Mutations of RyR2 Complex. Biophysical Journal, 2012, 102, 101a-102a.	0.5	0

#	Article	IF	Citations
451	Genetic Mechanisms of Arrhythmia. , 2012, , 601-623.		0
452	How to Interpret Results of Genetic Testing and Counsel Families. Cardiac Electrophysiology Clinics, 2012, 4, 97-101.	1.7	0
453	Sodium Current Disorders. Cardiac Electrophysiology Clinics, 2014, 6, 825-833.	1.7	0
454	Suppressed RyR2 Function Represents a Common Cause of Idiopathic Ventricular Fibrillation and Sudden Cardiac Death. Biophysical Journal, 2014, 106, 108a-109a.	0.5	0
455	GW26-e4570 Assessment of MESP1 in White Blood Cells May be Useful for Brugada Syndrome Diagnosis. Journal of the American College of Cardiology, 2015, 66, C78-C79.	2.8	0
456	Programmed ventricular stimulation early after myocardial infarction: authors' reply. Europace, 2016, 18, 789.2-790.	1.7	0
457	Suppression of Arrhythmia by Enhancing Mitochondrial Calcium Uptake in Experimental Models of Catecholaminergic Ventricular Tachycardia. Biophysical Journal, 2017, 112, 95a.	0.5	0
458	Arrhythmogenic Cardiomyopathy. Circulation Research, 2017, 121, 1296-1298.	4.5	0
459	Clinical timelines development from textual medical reports in Italian. , 2017, , .		0
460	Named lectures at ESC Congress 2018. European Heart Journal, 2018, 39, 4132-4136.	2.2	0
461	Molecular Basis of Mexiletine Response Variability in Sodium Channels with Long QT Mutations. Biophysical Journal, 2018, 114, 636a.	0.5	0
462	ESC Congress Programme Committee Chairs. European Heart Journal, 2019, 40, 408-408.	2.2	0
463	Cardiac Store Operated Calcium Entry (SOCE) is Compartmentalized at Intercalated Disks and Linked to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Biophysical Journal, 2019, 116, 236a.	0.5	0
464	What a Congress!. European Heart Journal, 2019, 40, 3507-3509.	2.2	0
465	Stabilizer Cells: a Less-is-More Gene Therapy Strategy to Prevent Cardiac Arrhythmias. Biophysical Journal, 2020, 118, 346a.	0.5	0
466	SOCE Contributes to Normal Calcium Homeostasis and Rythmic Activity of Atrial Myocardium. Biophysical Journal, 2020, 118, 406a.	0.5	0
467	ESC CONGRESS 2020â€"the digital experience: expanding the reach of the society. European Heart Journal, 2021, 42, 2812-2813.	2.2	0
468	Catecholaminergic Polymorphic Ventricular Tachycardia. , 2022, , 167-183.		0

#	Article	IF	Citations
469	Long QT Syndrome. , 2004, , 740-744.		0
470	Endocardial Implantation of a Cardioverter Defibrillator in Early Childhood. Journal of Cardiovascular Electrophysiology, 2006, .	1.7	0
471	Genetics of Inherited Arrhythmias. , 2007, , 502-513.		0
472	ONCO-i2b2: improve patients selection through CBR techniques with heterogeneous distance functions. EMBnet Journal, 2012, 18, 145.	0.6	0
473	Inheritable Phenotypes Associated With Altered Intracellular Calcium Regulation. , 2014, , 521-528.		0
474	Inherited Arrhythmias: LQTS/SQTS/CPVT. , 2018, , 413-435.		0
475	L-type Calcium Channel Disease. , 2008, , 187-193.		0
476	La estimulaciÃ³n elÃ©ctrica programada para la predicciÃ³n del riesgo en pacientes con sÃndrome de Brugada: Â¿tiempo de cierre?. Revista Espanola De Cardiologia, 2022, , .	1.2	0
477	764â€ƒPrevalence and clinical implications of cardiac involvement in individuals with paucisymptomatic SARS-CoV-2 infection. European Heart Journal Supplements, 2021, 23, .	0.1	0
478	769â€ƒDifferential pharmacological modulation of arrhythmic phenotype in catecholaminergic polymorphic ventricular tachycardia: not all betablockers are the same. European Heart Journal Supplements, 2021, 23, .	0.1	0
479	Programmed electrophysiological stimulation for risk prediction in patients with Brugada syndrome: closing time?. Revista Espanola De Cardiologia (English Ed), 2021, 75, 545-545.	0.6	0